Company intelligence / Profile preview

Greenbrook TMS

Toronto, Ontario, Canadagreenbrooktms.com ↗

Ownership: Private
Employees: ~489
Development stage: Other

Overview

Greenbrook has provided over 1.61 million treatments for depression and related disorders using FDA-cleared NeuroStar Transcranial Magnetic Stimulation and FDA-approved SPRAVATO® esketamine nasal spray. Both therapies are available at numerous outpatient centers across the United States and are covered by most insurance plans. The company focuses on patients who have not responded to traditional antidepressant medications.

Therapeutic areas: Psychiatry
Modalities: DeviceSmall moleculeNon-pharmacological therapy
Industry: Non-Academic Healthcare

Partnerships

Primary partnership implied with NeuroStar/Neuronetics for device supply.

Beyond the preview

Go deeper on Greenbrook TMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greenbrook TMS.

Explore the full profile